AAFP DISCLOSURES

It is the policy of the AAFP that all individuals in a position to control content disclose any relationships with commercial interests upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflicts of interest and if identified, they are resolved prior to confirmation of participation. Only these participants who have no conflict of interest or who agree to an identified resolution process prior to their participation were involved in this CME activity.

Dr. Gianutsos has no relevant financial relationships to disclose.

All other individuals in a position to control content for this activity have indicated they have no relevant financial relationships to disclose.

This educational activity is supported through the AAFP's in-cooperation-with agreement with the Collaborative for REMS Education (CO*RE), that received an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies (RPC). Please see www.er-la-opioidrems.com for a list of the member companies.

This activity is designed to be fully-compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration.


CO*RE DISCLOSURES

It is the policy of the CAFP that all individuals in a position to control content disclose any relevant financial relationships with manufacturer(s) of any commercial product(s) upon nomination/invitation of participation. Disclosure documents are reviewed for potential conflicts of interest and if identified, they are resolved prior to confirmation of participation. Only these participants who have no conflict of interest or who agree to an identified resolution process prior to their participation were involved in this CME activity.

The following CO*RE content developers have disclosed the following relevant financial relationships:

• Dr. Argoff – Grant/Research Support (Investigator) – Endo Pharmaceuticals, Lilly, Pfizer. Consultant (Advisor - Honorarium) - King Pharmaceuticals, Lilly, Pfizer. Speakers’ Bureau (Speaker – Honorarium) - Endo Pharmaceuticals, Lilly, Janssen. Shareholder – Pfizer.
• Dr. Stanos – Consultant (Honorarium) – Endo, Janssen, Pfizer.

All other individuals in a position to control content for this activity have indicated they have no relevant financial relationships to disclose.


AAFP DISCLAIMER

The material presented here is being made available by the American Academy of Family Physicians for educational purposes only. This material is not intended to represent the only, nor necessarily best, methods or procedures appropriate for the medical situations discussed. Rather, it is intended to present an approach, view, statement, or opinion of the faculty, which may be helpful to others who face similar situations.

The AAFP disclaims any and all liability for injury or other damages resulting to any individual using this material and for all claims that might arise out of the use of the techniques demonstrated therein by such individuals, whether these claims shall be asserted by a physician or any other person. Every effort has been made to ensure the accuracy of the data presented here. Physicians may care to check specific details such as drug doses and contraindications, etc., in standard sources prior to clinical application. This material might contain recommendations/guidelines developed by other organizations. Please note that although these guidelines might be included, this does not necessarily imply the endorsement by the AAFP.